Quest Diagnostics
DGX
#1095
Rank
ยฃ15.31 B
Marketcap
ยฃ136.91
Share price
-0.91%
Change (1 day)
11.28%
Change (1 year)
Quest Diagnostics is an American clinical laboratory company offering access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders and employment and court ordered drug testing.

Quest Diagnostics (DGX) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : ยฃ6.61 Billion

According to Quest Diagnostics 's latest financial reports the company's total liabilities are ยฃ6.61 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Quest Diagnostics - Total liabilities on balance sheet (from 2001 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31ยฃ7.37 B23.59%
2023-12-31ยฃ5.96 B5.72%
2022-12-31ยฃ5.64 B8.11%
2021-12-31ยฃ5.22 B-0.24%
2020-12-31ยฃ5.23 B-3.05%
2019-12-31ยฃ5.39 B21.11%
2018-12-31ยฃ4.45 B10.19%
2017-12-31ยฃ4.04 B-6.91%
2016-12-31ยฃ4.34 B24.37%
2015-12-31ยฃ3.49 B-1.56%
2014-12-31ยฃ3.54 B17.7%
2013-12-31ยฃ3.01 B-4.38%
2012-12-31ยฃ3.15 B-12.43%
2011-12-31ยฃ3.60 B24.29%
2010-12-31ยฃ2.89 B3.01%
2009-12-31ยฃ2.81 B-14.09%
2008-12-31ยฃ3.27 B24.1%
2007-12-31ยฃ2.63 B95.58%
2006-12-31ยฃ1.34 B-8.53%
2005-12-31ยฃ1.47 B47.83%
2004-12-31ยฃ0.99 B-6.41%
2003-12-31ยฃ1.06 B9.89%
2002-12-31ยฃ0.97 B-11.8%
2001-12-31ยฃ1.09 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
LabCorp
LH
ยฃ7.16 B 8.25%๐Ÿ‡บ๐Ÿ‡ธ USA
Psychemedics
PMD
ยฃ2.39 M-99.96%๐Ÿ‡บ๐Ÿ‡ธ USA
NeoGenomics
NEO
ยฃ0.40 B-93.92%๐Ÿ‡บ๐Ÿ‡ธ USA
Enzo Biochem
ENZB
ยฃ15.09 M-99.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Qiagen
QGEN
ยฃ2.17 B-67.08%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands